BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11846617)

  • 1. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Tentori L; Portarena I; Graziani G
    Pharmacol Res; 2002 Feb; 45(2):73-85. PubMed ID: 11846617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
    Nguewa PA; Fuertes MA; Valladares B; Alonso C; Pérez JM
    Prog Biophys Mol Biol; 2005 May; 88(1):143-72. PubMed ID: 15561303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
    Makogon NV; Aleksieieva IM
    Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions.
    Beneke S; Diefenbach J; Bürkle A
    Int J Cancer; 2004 Oct; 111(6):813-8. PubMed ID: 15300792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L; Szabó C
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Poly(ADP-ribose) polymerase-1 as a regulator of protein-nucleic acid interactions in the processes responding to genotoxic action].
    Sukhanova MV; Lavrik OI; Khodyreva SN
    Mol Biol (Mosk); 2004; 38(5):834-47. PubMed ID: 15554186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.
    Pogrebniak A; Schemainda I; Pelka-Fleischer R; Nüssler V; Hasmann M
    Eur J Med Res; 2003 Oct; 8(10):438-50. PubMed ID: 14594650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications.
    Sodhi RK; Singh N; Jaggi AS
    Vascul Pharmacol; 2010; 53(3-4):77-87. PubMed ID: 20633699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
    de la Lastra CA; Villegas I; Sánchez-Fidalgo S
    Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
    Decker P; Muller S
    Curr Pharm Biotechnol; 2002 Sep; 3(3):275-83. PubMed ID: 12164482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
    Jagtap P; Szabó C
    Nat Rev Drug Discov; 2005 May; 4(5):421-40. PubMed ID: 15864271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of poly(ADP-ribose) polymerase (PARP) influences the mode of sulfur mustard (SM)-induced cell death in HaCaT cells.
    Kehe K; Raithel K; Kreppel H; Jochum M; Worek F; Thiermann H
    Arch Toxicol; 2008 Jul; 82(7):461-70. PubMed ID: 18046540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase].
    Boulu RG; Mesenge C; Charriaut-Marlangue C; Verrecchia C; Plotkine M
    Bull Acad Natl Med; 2001; 185(3):555-63; discussion 564-5. PubMed ID: 11501263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
    Komjáti K; Besson VC; Szabó C
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose): PARadigms and PARadoxes.
    Bürkle A; Virág L
    Mol Aspects Med; 2013 Dec; 34(6):1046-65. PubMed ID: 23290998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Peroxynitrite-Induced Activation of Poly(ADP-Ribose) Polymerase (PARP) in Circulatory Shock and Related Pathological Conditions.
    Islam BU; Habib S; Ali SA; Moinuddin ; Ali A
    Cardiovasc Toxicol; 2017 Oct; 17(4):373-383. PubMed ID: 27990620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.